A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia [EXTENSION OF PROFILE 700206660].

Trial Profile

A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia [EXTENSION OF PROFILE 700206660].

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 02 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 15 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top